Osteoarthrosis patients with chronic pain
Conditions
Interventions
study group:buprenorphine transdermal patch 5mg/7days for 4 weeks
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Male or female aged 18 years or older; 2. Patient has been diagnosed as including but not limited to OA, or sacroiliitis, or retrograde spondylitis, or myofascitis; 3. Patient suffered from pain persisting for four weeks or longer; 4. Patient experienced invalid pain relief while taking non-steroidal anti-inflammatory drugs (NSAIDs) or paracetamol, or has NSAIDs contraindications; 5. Patient has an 'average pain over the last week' score at primary pain site of greater than or equal to 4 evaluated by one question (Please rate your pain by circling the one number that best describes your pain on the average pain over the last week) from Brief Pain Inventory (BPI); 6. Patient provides informed consent.
Exclusion criteria
Exclusion criteria: 1. Patient with a history of the drug or alcohol abuse. 2. Prior history of buprenorphine transdermal patch use. 3. Patient with allergies or other contraindications to transdermal systems or patch adhesives. 4. Patient with cancer pain. 5. patient with pain caused by Infectious disease; 6. Patient who participated in a clinical research study within one month of study entry; 7. Pregnant and lactating woman; 8. Patient who is not eligible for the study participation based on warnings, precautions and contra medications in the package insert of the study drug (at the investigators discretion).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of an average pain intensity over 24 hours from baseline through final evaluation as measured by BPI; | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate other patients’ pain relief parts using BPI scale from baseline through final evaluation;Quality of Life;Physician's and patient's satisfaction of using buprenorphine transdermal patch;early discontinuation;To describe the daily use of breakthrough pain medication by patients using buprenorphine transdermal patch;To describe the optimal dose level of buprenorphine transdermal patch at the end of titration;To describe the incidence and severity of adverse events of buprenorphine transdermal patch; | — |
Countries
China
Contacts
Public ContactPei Fuxing
West China Hospital, Sichuan University
Outcome results
None listed